Eiko Lifesciences Ltd — Board Meeting, 29-07-2025: Board Meeting

Eiko Lifesciences' board approved its quarterly financial results. Standalone profit after tax was Rs. 0.69 Cr on Rs. 8.01 Cr total revenue; consolidated profit reached Rs. 1.12 Cr on Rs. 10.98 Cr revenue. A major move is the increase in authorized share capital from Rs. 14 Cr to Rs. 20 Cr, which could fuel future growth and funding. The board also approved leadership changes: Mr. Umesh More's resignation as Whole Time Director, and Mr. Sumukh Vartak's appointment to that role. Independent Directors Ms. Kajal Kothari and Mr. Rajkumar Baheti were re-appointed. All await shareholder approval.